SCHEMBL9922940

SCHEMBL9922940

Cc1nc2ccc(S(N)(=O)=O)cc2c(=O)n1-c1ccc(NC(=O)NS(=O)(=O)c2ccc(Cl)s2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.54
CA12 O43570 7/20 0.44
CA1 P00915 7/20 0.44
CA2 P00918 7/20 0.44
CA9 Q16790 7/20 0.44
PPARG P37231 1/20 0.42
GRM1 Q13255 2/20 0.41
EGFR P00533 2/20 0.41
ERBB2 P04626 2/20 0.41
TP53 P04637 1/20 0.41
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA13 Q8N1Q1 1/20 0.40
CA14 Q9ULX7 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GRM5 P41594 1/20 0.40
NPC1 O15118 1/20 0.40
HPD P32754 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922163 0.93 P2RY12 (0.54) P2RY12PPARGTP53HSD17B10NPC1
SCHEMBL13638512 0.90 P2RY12 (0.57) P2RY12CA12CA1CA2CA9
SCHEMBL9922937 0.90 P2RY12 (0.57) P2RY12PPARGEGFRTP53NPC1
SCHEMBL9922397 0.90 P2RY12 (0.43) P2RY12CA12CA1CA2CA9
SCHEMBL9922158 0.88 P2RY12 (0.55) P2RY12PPARGEGFRTP53NPC1
SCHEMBL13638515 0.88 P2RY12 (0.55) P2RY12PPARGTP53NPC1HPD
SCHEMBL9922155 0.88 P2RY12 (0.59) P2RY12PPARGTP53NPC1HPD
SCHEMBL9922905 0.88 P2RY12 (0.49) P2RY12CA12CA1CA2CA9
SCHEMBL9922153 0.87 P2RY12 (0.54) P2RY12CA12CA1CA2CA9
SCHEMBL12161433 0.87 P2RY12 (0.54) P2RY12PPARGTP53NPC1HPD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2008-08-14 US disclosed
US-7358257-B2 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents PORTOLA PHARMACEUTICALS, INC. (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885CA12 4625/4885CA1 4531/4885
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PIGS, GP6, ASGR1 P2RY12 89/4885CA12 4701/4885CA1 4578/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885CA12 4616/4885CA1 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.